Highlights Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
3 ^USD	-1.64%		-1.96%	-6.83%

30/04	B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target	MT
29/04	HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Earnings Flash (OVID) OVID THERAPEUTICS Reports Q4 Revenue $141,562	08/03	MT
Ovid Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/03	CI
Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $108,972	03/11	MT
Ligand Acquires 13% Stake in Ovid Therapeutics' Soticlestat Royalties for $30 Million	18/23/18	MT
Earnings Flash (OVID) OVID THERAPEUTICS Posts Q2 Revenue $75,000	04/23/04	MT
Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Earnings Flash (OVID) OVID THERAPEUTICS Reports Q1 Revenue $66,160	05/23/05	MT
Ovid Therapeutics Inc. Enters into an Exclusive Collaboration and License Agreement with Graviton Bioscience Corporation	02/23/02	CI
Ovid Therapeutics, Graviton Bioscience Working Together to Create New Medicines for Neurological Diseases	01/23/01	MT
Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13	CI
Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13	CI
Earnings Flash (OVID) OVID THERAPEUTICS Posts Q4 Revenue $46, 280	13/23/13	MT
Ovid Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/23/13	CI
Ovid Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/23/13	CI
Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial	05/23/05	CI
Ovid Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08	CI
Earnings Flash (OVID) OVID THERAPEUTICS Posts Q3 Revenue $11,102	08/22/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Highlights

Filters